恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并NAFLD患者疗效初步研究

doi:10.3969/j.issn.1672-5069.2017.06.010

摘要/Abstract

摘要： 目的观察恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并非酒精性脂肪性肝病（NAFLD）患者的临床疗效及其对血清HBsAg、HBV DNA和血清肝纤维化指标的影响。方法2015年1月~2016年1月我院诊治的慢性乙型肝炎合并NAFLD患者80例,随机将患者分为对照组40例和观察组40例。对照组患者服用恩替卡韦,观察组患者服用恩替卡韦和水飞蓟宾葡甲胺,观察24 w。结果在治疗24 w末,观察组患者血清ALT和AST分别为（64.3±27.9）U/L和（42.0±24.5）U/L,均显著低于对照组【分别为（83.7±26.0）U/L和（57.6±26.6）U/L,P<0.05】;观察组血清Ⅲ型前胶原、Ⅳ型胶原蛋白、层粘连蛋白和透明质酸酶分别为（106.0±54.5）ng/L、（69.23±21.24）ng/L、（119.2±61.2）ng/L和（119.2±71.2）ng/L,均显著低于对照组【（147.6±76.6）ng/L、（86.74±21.30）ng/、（212.7±100.3）ng/L和（205.7±91.3）ng/L,P<0.05】;观察组与对照组患者血清HBV DNA水平分别为（2.3±0.9）Ig IU/ml和（2.7±1.0）Ig IU/ml,血清HBsAg水平分别为（4458.0±945.5）S/CO和（4744.0±1256.5）S/CO,差异均无统计学意义。结论应用恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并NAFLD患者较恩替卡韦单药治疗可以更有效地改善肝酶谱及血清肝纤维化指标,但对血清HBsAg水平无明显影响。

关键词: 乙型肝炎, 非酒精性脂肪性肝病, 恩替卡韦, 水飞蓟宾葡甲胺, 治疗

Abstract: Objective To observe the efficacy of entecavir combined with silybin meglumine amine in treatment of patients with chronic hepatitis B （CHB） and non-alcoholic fatty liver disease （NAFLD）. Methods 80 patients with CHB and NAFLD in our hospital were enrolled between January 2015 and January 2016 in this study. Patients were randomly divided into control group and observation group with 40 cases in each group. The patients in control group was treated with entecavir alone and in observation group was given entecavir combined with silybin meglumine amine. The regimen continued in both groups,and we assessed the efficacy at the end of six month treatment. Results At the end of six month treatment,serum alanine aminotransferase and aspartate amonotransferase levels in observation group were significantly lower than those in the control group[（64.3±27.9） U/L vs. （83.7±26.0） U/L,and （42.0±24.5） U/L vs. （57.6±26.6） U/L,respectively,P<0.05 for both];serum levels of PCⅢ,Ⅳ-C,LN and HA in observation group were lower than those in the control group [（106.0±54.5） ng/L vs. （147.6±76.6） ng/L,（69.23±21.24） ng/L vs. （86.74±21.30） ng/L,（119.2±61.2） ng/L vs. （212.7±100.3） ng/L,and （119.2±71.2） ng/L vs. （205.7±91.3） ng/L,respectively,P<0.05 for all];there were no differences as respect to serum HBV DNA and HBsAg levels between the two groups [（2.3±0.9） Ig IU /ml vs. （2.7±1.0） Ig IU /ml,and （4458.0±945.5） S/CO vs. （4744.0±1256.5） S/CO,respectively,P<0.05 for both]. Conclusion The combination of entecavir and silybin meglumine amine is effective in improving liver enzymes and serum indexs of hepatic fibrosis in patients with CHB and NAFLD,but we don’t find any benefit on serum HBsAg eradication by this regimen.

Key words: Hepatitis B, Non-alcoholic fatty liver disease, Entecavir, Silybin meglumine amine, Therapy

李旭. 恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并NAFLD患者疗效初步研究[J]. 实用肝脏病杂志, 2017, 20(6): 676-679.

Li Xu. Preliminary study of the efficacy of entecavir combined with silybin neglumine amine in treatment of patients with chronic hepatitis B and NAFLD[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 676-679.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南.实用肝脏病杂志，2006，9（6）:321-324.
[2] Chen LY，Yang B，Zhou L，et al. Promotion of mitochondrialenergy metabolism during hepatocyte apoptosis in a rat model of acute liverfailure. Mol Med Rep，2015，12（4）:5035-5041.
[3] Crompton M. The mitochondrial permeability transition pore and its role in cell　death. Biochem J，1999，341（2）:233-249.
[4] Halestrap AP. The mitochondrial permeability transition:its mol-ecular mechanism and role in reperfusion injury. Biochem Soc Symp，1999，66:181-203.
[5] Halestrap AP，McStay GP，Clarke SJ. The permeability transition pore complex:another view.Biochimie，2002，84（2-3）:153-166.
[6] Zhang Q，Yang F，Li X，et al. Trichostatin A protects against intestinal injury in rats with acute liver failure. J Surg Res，2016，205（1）:1-10.
[7] 张海月，李讯，张倩，等. MS-275对急性肝衰竭小鼠肝脏的保护作用. 中华临床感染病杂志. 2016，9（4）:325-330.
[8] Bernal W，Auzinger G，Dhawan A，et al. Acute liver failure. Lancet，2010，376（9736）:190-201.
[9] Cardoso FS，Marcelino P，Bagulho L，et al. Acute liver failure: An up-to-date approach. J Crit Care，2017，39:25-30.
[10] 丁美，刘旭华，段钟平. D-氨基半乳糖/脂多糖诱导急性肝衰竭大鼠肝细胞凋亡的电镜观察. 实用肝脏病杂志. 2008，11（6）:357-360.
[11] Laubach JP，San-Miguel JF，Hungria V，et al. Deacetylase inhibitors:an advance in myeloma therapy. Expert Rev Hematol，2017，1:1-9.
[12] Buurman R，Sandbothe M，Schlegelberger B，et al. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma. Eur J Med Res，2016，21（1）:26.
[13] Pan CH，Chang YF，Lee MS，et al. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.BMC Cancer，2016，16（1）:857.
[14] Nakagawa Y，Suzuki T，Kamimura H，et al. Role of mitochondrial membrane permeability transition in N-nitrosofenfluramine-induced cell injury in rat hepatocytes. Eur J Pharmacol，2006，529（1-3）:33-39.
[15] Joza N，Susin SA，Daugas E，et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature，2001，410（6828）:549-554.
[16] Hüttemann M，Helling S，Sanderson TH，et al. Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome C oxidase and cytochrome C in ischemia/reperfusion injury and inflammation. Biochim Biophys Acta，2012，1817（4）:598-609.
[17] Sesso A1，Marques MM，Monteiro MM，et al. Morphology of mitochondrial permeability transition:morphometric volumetry in apoptotic cells. Anat Rec A Discov Mol Cell Evol Biol，2004，281（2）:1337-1351.
[18] 武磊，刘晓华，王天辉. 组蛋白去乙酰化酶抑制剂对大鼠应激性心肌损伤的保护作用. 中国应用生理学杂志，2015，31（3）:193-196.
[19] Chang Z1，Li Y，He W，et al. Selective inhibition of histone deacetylase 6 promotes survival in a rat model of hemorrhagic shock. J Trauma Acute Care Surg，2015，79（6）:905-910.
[20] Li S，Tang Z，Yu H et al. Administration of naked plasmid encoding hepatic stimulator substance by hydrodynamic tail vein injection protects mice from hepatic failure by suppressing the mitochondrial permeability transition. J Pharmacol Exp Ther，2011，338（3）:750-757.